AbbVie Invests $195 Million in New Illinois API Facility

North Chicago, IL – August 2025
AbbVie has announced a $195 million investment to build a new active pharmaceutical ingredient (API) facility in North Chicago, Illinois, with construction slated to begin in late 2025. The facility will enhance AbbVie’s domestic production capacity for medicines in neuroscience, immunology, and oncology, reinforcing its commitment to U.S.-based manufacturing.

This investment aligns with broader industry trends toward strengthening domestic supply chains. The new facility will support AbbVie’s growing portfolio and contribute to local economic growth through job creation. Specific details on job numbers and completion timelines remain undisclosed, but the project underscores AbbVie’s strategic focus on advancing innovative therapies from its U.S. operations.